Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly

Acromegaly Clinical Trial

— LANTERN  

Official title:

A Phase III, Prospective, Randomised, Open Label Study to Compare the Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg PR in Subjects With Active Acromegaly

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02493517
• Other study ID #: 8-55-52030-289
• Secondary ID: CTR20140698
• Status: Completed
• Phase: Phase 3
• Start date: October 2014
• Est. completion date: February 16, 2017

Study information

• Verified date: January 2019
• Source: Ipsen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose is to compare the efficacy and safety of lanreotide autogel® 60mg, 90mg or 120mg with lanreotide 40mg PR in subjects with active acromegaly.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 128
• Est. completion date: February 16, 2017
• Est. primary completion date: November 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Subject has active acromegaly defined as elevated GH and IGF-1 levels (measured at a central laboratory) as outlined below:

• A serum level for IGF-1 =1.3 x upper limit of normal range (ULN) during the screening period (applicable to both treatment naïve subjects and subjects who have stopped treatment and undergone a washout period prior to Visit 1(Week -4).

• Subjects must have mean serum GH concentration =2.5 µg/L in a GH cycle (5 samples taken at 0, 30, 60, 90 and 120 minutes) during the screening period.

• The subject has undergone surgical removal of an adenoma for acromegaly at least 3 months prior to Screening, or is likely to require pituitary surgery in the future but not before completing at least 32 weeks of study treatment plus an additional follow up of 8 weeks for subjects taking part in the pharmacokinetics (PK) extension, or for whom pituitary surgery is not an option (due to contraindications, refusal etc.) and is therefore never likely to undergo pituitary surgery.

Exclusion Criteria:

• The subject has been treated with radiotherapy within 10 years prior to Screening.

• The subject has been treated with lanreotide Autogel, lanreotide PR, pegvisomant, cabergoline or octreotide LAR within 3 months of Screening or octreotide immediate release (IR) or bromocriptin within 2 weeks of Screening.

• The subject has a history of or currently presents with clinically significant ventricular or atrial dysrhythmias =Grade 2, using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0.

• The subject has uncontrolled diabetes (glycosylated haemoglobin (HbA1c) >8.5%).

Related Conditions & MeSH terms

• Acromegaly

Intervention

Drug:
• Lanreotide Autogel®
Lanreotide Autogel 60mg, 90mg, and 120mg, pre-filled syringe, deep subcutaneous injection (provided as a supersaturated solution of lanreotide acetate).
• Lanreotide Acetate
Lanreotide PR 40mg white freeze-drying cake, 40mg/vial, deep subcutaneous injection (provided as a sterile injectable lyophilisate of lanreotide acetate).

Locations

Country	Name	City	State
China	Peking Union Medical College Hospital	Beijing
China	West China Hospital, Sichuan University	Chengdu
China	Fujian Provincial Hospital	Fuzhou
China	The First Affiliated Hospital, Sun Yat-sen University	Guangzhou
China	Affiliate Hospital of Guiyang Medical College	Guizhou
China	Jiangsu Provincial People's Hospital	Nanjing
China	Huashan Hospital Fudan University	Shanghai
China	The Second Hospital of Hebei Medical University	Shijiazhuang
China	Tianjin Medical University General Hospital	Tianjin
China	Tongji Medical College Huazhong University of Science & Technology	Wuhan

Sponsors (1)

Lead Sponsor	Collaborator
Ipsen

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Standardised Mean Change From Baseline in Age-adjusted IGF-1 Levels at the EOST/EW Visit	The standardised mean change from Baseline in age-adjusted log-transformed IGF-1 standard deviation score (SDS) at EOST/EW is presented for subjects treated with both lanreotide Autogel and lanreotide PR. Back-transformed results are presented in addition to the results without back-transformation.; For each subject the IGF-1 SDS value was calculated based on the z-score derivation: IGF-1 SDS = (IGF-1 - mean)/ standard deviation (SD), with mean and SD derived from the upper limit of normal (ULN) and lower limit of normal (LLN) margins for each age category. ULN = Mean + 2 SD; LLN = Mean - 2 SD.; The SDS indicates the number of standard deviations away from the mean. A SDS of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. A negative change in the SDS indicates a decrease in the mean age-adjusted IGF-1 values.	Baseline to EOST/EW Visit (up to Week 33 for the lanreotide Autogel group and up to Week 32 for the lanreotide PR group).
Secondary	Percentage of Subjects With Normal Age-adjusted IGF-1 Levels at the EOST/EW Visit	The percentage of subjects with normal age-adjusted IGF-1 levels at the EOST/EW Visit is presented for subjects treated with Lanreotide Autogel and Lanreotide PR.; At baseline, all subjects had abnormal IGF-1 levels as per protocol entry criteria.	Baseline to EOST/EW Visit (up to Week 33 for the lanreotide Autogel group and up to Week 32 for the lanreotide PR group).
Secondary	Percentage of Subjects With GH =2.5 Micrograms Per Litre (mcg/L) at the EOST/EW Visit	The percentage of subjects with GH =2.5 mcg/L at the EOST/EW Visit is presented for subjects treated with lanreotide Autogel and lanreotide PR.; At baseline, all subjects had GH levels >2.5 mcg/L as per protocol entry criteria.	Baseline to EOST/EW Visit (up to Week 33 for the lanreotide Autogel group and up to Week 32 for the lanreotide PR group).
Secondary	The Percentage of Subjects With GH =1 mcg/L at the EOST/EW Visit	The percentage of subjects with GH =1 mcg/L at the EOST/EW Visit is presented for subjects treated with lanreotide Autogel and lanreotide PR.; At baseline, all subjects had GH levels >2.5 mcg/L as per protocol entry criteria.	Baseline to EOST/EW Visit (up to Week 33 for the lanreotide Autogel group and up to Week 32 for the lanreotide PR group).
Secondary	Percentage of Subjects With Normal Age-adjusted IGF-1 Levels and Who Have GH Levels >1 mcg/L and =2.5 mcg/L at the EOST/EW Visit	The percentage of subjects with normal age-adjusted IGF-1 levels and who have GH levels >1 mcg/L but =2.5 mcg/L at the EOST/EW Visit is presented for subjects treated with lanreotide Autogel and lanreotide PR. The calculation of percentages was based on the overall ITT population.; At baseline, all subjects had abnormal IGF-1 levels and GH levels >2.5 mcg/L as per protocol entry criteria.	Baseline to EOST/EW Visit (up to Week 33 for the lanreotide Autogel group and up to Week 32 for the lanreotide PR group).
Secondary	Mean Change From Baseline in GH Values at the EOST/EW Visit	The mean change from baseline in GH values at the EOST/EW Visit is presented for subjects treated with lanreotide Autogel and lanreotide PR.	Baseline to EOST/EW Visit (up to Week 33 for the lanreotide Autogel group and up to Week 32 for the lanreotide PR group).
Secondary	Percentage of Subjects With at Least 20% Reduction in Tumour Volume at EOST/EW Visit Compared to Baseline	The percentage of subjects with at least a 20% reduction in the solid component of the tumour volume at the EOST/EW Visit compared to baseline is presented for the subgroup of subjects who had solid tumours at baseline.; The tumour volume was measured by Magnetic Resonance Imaging (MRI) at Screening and at the EOST/EW Visit, and then assessed by two independent blinded readers.	Baseline to EOST/EW Visit (up to Week 33 for the lanreotide Autogel group and up to Week 32 for the lanreotide PR group).
Secondary	Median Percentage Change From Baseline in Tumour Volume at the EOST/EW Visit	The median percentage change in the solid component of the tumour volume from baseline to the EOST/EW Visit is presented.; The tumour volume was measured by MRI at Screening and at the EOST/EW Visit, and then assessed by two independent blinded readers.	Baseline to EOST/EW Visit (up to Week 33 for the lanreotide Autogel group and up to Week 32 for the lanreotide PR group).
Secondary	Percentage of Subjects With at Least One Symptom of Acromegaly at Week 13 and at the EOST/EW Visit Compared to Baseline	The percentage of subjects with at least one symptom of acromegaly at Week 13 and at the EOST/EW Visit compared with baseline is presented for subjects treated with lanreotide Autogel and lanreotide PR. The symptoms of acromegaly monitored included: headache, excessive perspiration, fatigue, soft tissue swelling and arthralgia.	Baseline, Week 13 Visit and EOST/EW Visit (up to Week 33 for the lanreotide Autogel group and up to Week 32 for the lanreotide PR group).